Superworth

Fortrea revenue FTRE

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
$2.7B
Latest quarter, Q2 FY26
$678.2M
−5% on a year earlier
Fiscal year 2025
$2.7B
+1% on the year before

Fortrea's revenue was $2.7B over the twelve months to Jun 30, 2026, down 2% on a year earlier.

In its latest quarter, Q2 FY26, it was $678.2M, down 5% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$2.7B+1%
FY2024$2.7B−5%
FY2023$2.8B−8%
FY2022$3.1Bn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$678.2M−5%$2.7B
Q1 FY26$636.5M−2%$2.7B
Q4 FY25$660.5M−5%$2.7B
Q3 FY25$701.3M+4%$2.8B
Q2 FY25$710.3M+7%$2.7B
Q1 FY25$651.3M−2%$2.7B
Q4 FY24$697M−2%$2.7B
Q3 FY24$674.9M−5%$2.7B
Q2 FY24$662.4M−9%$2.7B
Q1 FY24$662.1M−5%$2.8B
Q4 FY23$709.7M−7%$2.8B
Q3 FY23$713.8M−6%$2.9B

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
FTREFortrea$2.7B−2% a year
CDNACareDx$458.1M+34% a year
VCYTVeracyte$561.9M+17% a year
BLLNBillionToOne$397.4M+90% a year
LNTHLantheus$1.6B+2% a year
CAICaris Life Sciences$989.6M+85% a year
BIOBio-Rad Laboratories$2.6B+1% a year
NRCNRC Health$140M−0% a year
RVTYRevvity$2.9B+4% a year
MEDPMedpace$2.8B+25% a year
Peer median$989.6M

Where Fortrea ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Fortrea

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.